CD34 and acute myeloid leukemia: Our results are in accordance with previously reported findings, as all three drugs enhanced dual ABCB1 and ABCG2 mitoxantrone substrate accumulation in CD34+ AML blasts while not affecting the intracellular levels of mitoxantrone in PBMC obtained from CD34− patients.